Research progress of driving gene and molecular targeting therapy for non-small cell lung cancer
10.3760/cma.j.issn.1008-6706.2020.03.032
- VernacularTitle: 非小细胞肺癌驱动基因及分子靶向治疗研究进展
- Author:
Jiaxing KANG
1
;
Jingyuan WANG
Author Information
1. Basic Medical College, Inner Mongolia Medical University, Huhehaote, Inner Mongolia 010010, China
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Carcinoma, non-small-cell lung;
Driving genes;
Molecular targeted therapy;
Driving gene related inhibitor;
Molecular detection technique;
Genic mutation;
Clinical application;
Individualized treatment;
Drug resistance
- From:
Chinese Journal of Primary Medicine and Pharmacy
2020;27(3):381-384
- CountryChina
- Language:Chinese
-
Abstract:
The morbidity and mortality of lung cancer are the highest in China, and the non-small cell lung cancer(NSCLC) is the first one, accounting for about 80% of lung cancer.NSCLC includes squamous cell carcinoma, adenocarcinoma, etc.Because of the slow growth of lung cancer cells and the late diffusion and metastasis, most of the patients were in late stage and lost the best period of surgical treatment.In recent years, molecular targeted therapy for specific genes has become an important strategy for the treatment of NSCLC.Multiple target genes, such as EGFR, KRAS, BRAF and EML4-ALK have been identified.This article reviews the related driving genes and molecular targeted therapy of NSCLC, expecting to be helpful to the individualized treatment of advanced NSCLC patients.
